Biocardia Company Insiders
BCDA Stock | USD 2.84 0.12 4.41% |
Biocardia employs about 16 people. The company is managed by 6 executives with a total tenure of roughly 18 years, averaging almost 3.0 years of service per executive, having 2.67 employees per reported executive. Analysis of Biocardia's management performance can provide insight into the company performance.
Peter Altman CEO President CEO, Principal Executive Officer, Director |
David McClung President Principal Financial and Accounting Officer, Vice President - Finance |
Biocardia |
Biocardia Management Team Effectiveness
The company has return on total asset (ROA) of (0.9691) % which means that it has lost $0.9691 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.3789) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities.Biocardia Workforce Comparison
Biocardia is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 819. Biocardia claims roughly 16.0 in number of employees contributing just under 2% to equities under Health Care industry.
Biocardia Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biocardia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Peter Altman over a week ago Acquisition by Peter Altman of 600 shares of Biocardia at 2.48 subject to Rule 16b-3 | ||
Peter Altman over two weeks ago Acquisition by Peter Altman of 2 shares of Biocardia at 2.38 subject to Rule 16b-3 | ||
Peter Altman over two weeks ago Acquisition by Peter Altman of 500 shares of Biocardia at 2.4 subject to Rule 16b-3 | ||
Peter Altman over a month ago Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 | ||
Edward Gillis over a month ago Disposition of 3257 shares by Edward Gillis of Biocardia at 2.0 subject to Rule 16b-3 | ||
Peter Altman over two months ago Acquisition by Peter Altman of 41666 shares of Biocardia at 3.0 subject to Rule 16b-3 | ||
Allen Jim L. over three months ago Acquisition by Allen Jim L. of 12434 shares of Biocardia at 4.43 subject to Rule 16b-3 | ||
Allen Jim L. over three months ago Acquisition by Allen Jim L. of 829 shares of Biocardia at 2.65 subject to Rule 16b-3 |
Biocardia Notable Stakeholders
A Biocardia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biocardia often face trade-offs trying to please all of them. Biocardia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biocardia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peter Altman | President CEO, Principal Executive Officer, Director | Profile | |
David McClung | Principal Financial and Accounting Officer, Vice President - Finance | Profile | |
Edward Gillis | Senior Devices | Profile | |
Ian McNiece | Chief Officer | Profile | |
Sujith Shetty | Chief Regulatory | Profile | |
Sujith MBBS | Chief Regulatory | Profile |
About Biocardia Management Performance
The success or failure of an entity such as Biocardia often depends on how effective the management is. Biocardia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biocardia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biocardia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Please note, the presentation of Biocardia's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.
Biocardia Workforce Analysis
Traditionally, organizations such as Biocardia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biocardia within its industry.Biocardia Manpower Efficiency
Return on Biocardia Manpower
Revenue Per Employee | 29.8K | |
Revenue Per Executive | 79.5K | |
Net Loss Per Employee | 723.2K | |
Net Loss Per Executive | 1.9M |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |